<DOC>
	<DOCNO>NCT01642407</DOCNO>
	<brief_summary>Pulmonary arterial hypertension ( PAH ) rare , progressive , life-threatening disease . In many patient , course PAH steady deterioration reduce life expectancy . Sildenafil approve European Commission treatment PAH pediatric patient May 2011 , make first agent approve treatment child PAH . The approval base large placebo-controlled study conduct population . The recommend dose pediatric patient age 1 year 17 year old 10 mg TID patient ≤ 20 kg 20 mg TID patient &gt; 20 kg . Higher dos recommend pediatrics patient . This study open-label , multi-center study investigate safety , efficacy pharmacokinetics sildenafil citrate Japanese pediatric patient PAH .</brief_summary>
	<brief_title>Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Subjects weigh ≥8 kg . Subjects symptomatic pulmonary arterial hypertension due one follow condition : Idiopathic pulmonary arterial hypertension ; Heritable pulmonary arterial hypertension ; Pulmonary arterial hypertension associate congenital systemictopulmonary shunt . If defect ( ) repair , subject 's condition stabilize hemodynamically ; Pulmonary arterial hypertension associate dtransposition great artery repair within first 30 day life ; Pulmonary arterial hypertension subject undergone surgical repair congenital heart lesion condition stabilize hemodynamically clinically significant residual leftsided heart disease . Subjects mean pulmonary artery pressure ≥25 mmHg rest , PCWP ≤15 mmHg , PVRI ≥3 Wood unit x m2 . If PCWP available , mean LA pressure ≤15 mmHg LVEDP ≤15 mmHg absence leave atrial obstruction . Leftsided heart disease . Subjects Down syndrome . Subjects Obstructive Sleep Apnea , regardless treatment status . Pericardial constriction . Subjects significant ( 2+ regurgitation ) valvular disease tricuspid pulmonary regurgitation . Acutely decompensated heart failure within previous 30 day screen . Subjects atrial septostomy within previous 6 month screen . Subjects hemodynamic instability hypo hypertension screen . Subjects history stroke , myocardial infarction life threaten arrhythmia within 6 month screen . Subjects moderate severe restrictive pulmonary disease ( Total Lung Capacity Forced Vital Capacity ≤60 % normal ) history severe lung disease . Subjects bronchopulmonary dysplasia ( BPD ) chronic lung disease . Subjects history pulmonary embolism . Subjects know hereditary degenerative retinal disorder ( retinitis pigmentosa ) history nonarteritic anterior ischemic optic neuropathy ( NAION ) . Subjects know HIV positive . Subjects impairment renal function ( serum creatinine &gt; 2.5 × ULN ) hepatic function ( ALT and/or AST &gt; 3 × ULN ; and/or bilirubin ≥2 mg/dL ) . Hematological abnormality ( e.g. , severe anemia , Hgb &lt; 10 g/dL , leukopenia , WBC &lt; 2500/µL ) . Subjects severe hepatic dysfunction ( ChildPugh classification C ) . Change class medication CHF PAH within 10 day prior qualify right heart catheterization . Subjects currently prescribe and/or take nitrate nitric oxide donor form . Subjects take chronic arginine supplementation . Subjects received parenteral inotropic medication parenteral vasodilator within 30 day Day 1 . Subjects receive alphablockers , nicorandil , amiodarone potent cytochrome P450 3A4 inhibitor . Subjects receive chronic treatment offlabel sildenafil within 30 day Day 1 exclude . Subjects receive endothelin antagonist，PED5 inhibitor , prostacyclin/prostacyclin analogue within 30 day randomization exclude except beraprost . Pregnant female ; breastfeed female ; male females childbearing potential use highly effective contraception agree continue highly effective contraception least 28 day last dose investigational product . Current past illicit drug use alcoholism except abstinence document ≥1 year . Participation another clinical trial investigational drug device ( include placebo ) within 30 day screen entry present study . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>